Aisling Capital Management’s Tourmaline Bio TRML Stock Holding History

Aisling Capital Management’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-17,500	Closed	-$460K	–	17
2022 Q3	$460K	Sell	17,500 -50,792	-74%	-$1.85M	0.31%	17
2022 Q2	$3.08M	Hold	68,292	–	–	2.2%	9
2022 Q1	$6.72M	Hold	68,292	–	–	3.63%	8
2021 Q4	$10.4M	Hold	68,292	–	–	3.68%	7
2021 Q3	$9.26M	Hold	68,292	–	–	1.85%	10
2021 Q2	$10M	Buy	+68,292	New	+$10.5M	1.61%	12

Other funds holding TRML

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

QUSVM

Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aisling Capital Management's TRML Position: Q4 2022 in Review

Aisling Capital Management sold out of Tourmaline Bio (TRML) in Q4 2022, closing a stake of 17,500 shares — an estimated $460K sold.

Aisling Capital Management first reported a position in TRML in Q2 2021 and held it in 6 quarters. The position peaked at $10.4M in Q4 2021. 53 funds tracked by Wall St. Rank hold TRML as of Q4 2022.

Aisling Capital Management reported no remaining Tourmaline Bio position as of Q4 2022 after selling out during the quarter.
Aisling Capital Management sold 17,500 Tourmaline Bio shares in Q4 2022, an estimated $460K.
Aisling Capital Management first reported a position in Tourmaline Bio in Q2 2021 and held it in 6 quarters.
Aisling Capital Management's Tourmaline Bio position peaked at $10.4M in Q4 2021.
53 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2022.

Based on Aisling Capital Management's 13F filing for Q4 2022, filed 9 Feb 2023.